The Retinal Degeneration drugs in development market research report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinal Degeneration. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Retinal Degeneration - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinal Degeneration and features dormant and discontinued products.

GlobalData tracks 76 drugs in development for Retinal Degeneration by 63 companies/universities/institutes. The top development phase for Retinal Degeneration is preclinical with 40 drugs in that stage. The Retinal Degeneration pipeline has 66 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Retinal Degeneration pipeline products market are: VCCT, Opus Genetics and Wuhan Neurophth Biological Technology.

The key targets in the Retinal Degeneration pipeline products market include Centrosomal Protein Of 290 kDa (Bardet Biedl Syndrome 14 Protein or Cancer/Testis Antigen 87 or Nephrocystin 6 or Tumor Antigen se2-2 or CEP290), Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64), and Retinoschisin (X Linked Juvenile Retinoschisis Protein or RS1).

The key mechanisms of action in the Retinal Degeneration pipeline product include Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64) Activator with five drugs in Phase II. The Retinal Degeneration pipeline products include nine routes of administration with the top ROA being Intraocular and eight key molecule types in the Retinal Degeneration pipeline products market including Gene Therapy, and Small Molecule.

Retinal Degeneration overview

Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis pigmentosa (RP): RP is a genetic disorder that affects the retina’s rod and cone cells, leading to a gradual loss of peripheral vision and difficulty seeing in low light. Over time, it can progress to tunnel vision or complete blindness. Age-related macular degeneration (AMD): AMD primarily affects the macula, the central part of the retina responsible for detailed central vision. It is more common in older individuals and can lead to blurred or distorted central vision, making it difficult to read or recognize faces. Stargardt disease: Stargardt disease is an inherited form of macular degeneration that usually manifests in childhood or adolescence. It causes progressive central vision loss due to the degeneration of the macula. Choroideremia: Choroideremia is a rare genetic disorder affecting the retina’s photoreceptor cells, leading to progressive vision loss that typically begins in childhood and worsens over time. Leber congenital amaurosis (LCA): LCA is a rare inherited disorder causing severe vision loss or blindness at birth or within the first few months of life. It affects the development of the retina and its ability to perceive light. Symptoms of retinal degeneration can vary based on the specific condition and its stage, but they often include reduced night vision, difficulty seeing in low light, loss of peripheral or central vision, and, in some cases, changes in color perception.

For a complete picture of Retinal Degeneration’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.